isavuconazonium sulfate

G2203 is a generic small molecule antifungal agent developed by BCWorld Pharma, a South Korean pharmaceutical company. It is a generic version of **isavuconazonium sulfate**, a prodrug that is rapidly converted to the active triazole antifungal **isavuconazole**. The drug's mechanism of action involves the inhibition of **lanosterol 14-alpha demethylase** (CYP51), a cytochrome P450-dependent enzyme essential for fungal cell membrane synthesis. By inhibiting this enzyme, G2203 prevents the conversion of lanosterol to ergosterol, leading to the depletion of ergosterol and the accumulation of toxic methylated sterol precursors, which ultimately results in fungal cell death. G2203 is being developed for the treatment of invasive fungal infections, including invasive aspergillosis and mucormycosis, and is currently in the clinical stage of development, typically involving bioequivalence studies for generic approval in South Korea.

Other names

isavuconazoleisavuconazonium